atazanavir sulfate has been researched along with bilirubin in 53 studies
Studies (atazanavir sulfate) | Trials (atazanavir sulfate) | Recent Studies (post-2010) (atazanavir sulfate) | Studies (bilirubin) | Trials (bilirubin) | Recent Studies (post-2010) (bilirubin) |
---|---|---|---|---|---|
1,102 | 246 | 590 | 25,921 | 1,337 | 5,871 |
Protein | Taxonomy | atazanavir sulfate (IC50) | bilirubin (IC50) |
---|---|---|---|
Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 3.3884 | |
Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 1.3183 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 12 (22.64) | 29.6817 |
2010's | 38 (71.70) | 24.3611 |
2020's | 3 (5.66) | 2.80 |
Authors | Studies |
---|---|
Chando, TJ; Dehal, SS; Everett, DW; Humphreys, WG; Patten, CJ; Zhang, D | 1 |
Christensen, AR; Furtek, KJ; Hale, BR; Jones, LE; Petersen, K; Riddle, MS; Tasker, SA | 1 |
Dellamonica, P | 1 |
Gold, J; Jeganathan, S; Smith, D | 1 |
Back, D; Boffito, M; Dickinson, L; Fletcher, C; Gazzard, B; Hill, A; Maitland, D; Moyle, G; Nelson, M; Pozniak, A | 1 |
Josephson, F; Karlström, O; Sönnerborg, A | 1 |
Burger, DM; Cleijsen, RM; de Wolf, F; Gras, L; Koopmans, PP; Kroon, FP; Lunel, FV; van de Ende, ME | 1 |
Blanco, A; Clotet, B; Miranda, C; Miranda, J; Moltó, J; Negredo, E; Santos, JR; Valle, M | 1 |
Abdel-Kader, L; Camacho, A; Lozano, F; Macías, J; Palacios, R; Pineda, JA; Rivero, A; Santos, J | 1 |
Ehmer, U; Lankisch, TO; Manns, MP; Strassburg, CP | 1 |
Barreiro, P; García-Gascó, P; González-Pardo, G; Jiménez-Nácher, I; Maida, I; Morello, J; Parra, A; Rodríguez-Nóvoa, S; Soriano, V; Vispo, E | 1 |
Barreiro, P; González, M; Gonzalez-Lahoz, J; González-Pardo, G; Jiménez-Nácher, I; Morello, J; Rodríguez-Nóvoa, S; Soriano, V; Vispo, E | 1 |
Andersson, MC; Böttiger, Y; Flamholc, L; Gisslén, M; Hagberg, L; Josephson, F; Ormaasen, V; Sönnerborg, A; Vesterbacka, J | 1 |
Cauda, R; Colafigli, M; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Navarra, P; Prosperi, M; Ragazzoni, E | 1 |
Choe, KW; Choe, PG; Jeon, JH; Kim, HB; Kim, NJ; Oh, MD; Park, SW; Park, WB; Song, KH | 1 |
Burger, DM; Dekker, D; Dorresteijn, MJ; Heemskerk, S; Pijnenburg, M; Rasing-Hoogveld, A; Smits, P; Wagener, FA | 1 |
Bellón, JM; González, MI; José, MI; Larru, B; Mellado, MJ; Muñoz-Fernández, MÁ; Navarro, ML; Nso Roca, AP; Nso, AP; Ramos, JT | 1 |
Barassi, A; Bini, T; Biondi, ML; Casana, M; Cicconi, P; d'Arminio Manforte, A; d'Eril, GM; Marchetti, GC; Pateri, F; Turri, O | 1 |
Alvarez, E; Cuenca, L; González-Lahoz, J; Morello, J; Rodríguez-Nóvoa, S; Soriano, V; Vispo, E | 1 |
Casado, JL; Dronda, F; Hermida, JM; Hernandez-Novoa, B; Moreno, A; Moreno, S; Perez-Elias, MJ; Quereda, C; Rodriguez, JM; Rodriguez, MA | 1 |
Honda, M; Ishisaka, M; Ishizuka, N; Kimura, S; Oka, S | 1 |
Azria, E; Crenn-Hebert, C; Ferreira, C; Floch-Tudal, C; Herinomenzanahary, E; Mandelbrot, L; Mazy, F; Meier, F; Peytavin, G; Treluyer, JM | 1 |
Bower, M; Gazzard, B; Mandalia, S; Nelson, M; Rockwood, N | 1 |
Abelö, A; Ashton, M; Clewe, O; Flamholc, L; Gisslén, M; Ormaasen, V; Rekić, D; Röshammar, D; Sönnerborg, A | 1 |
Agnes, G; Basso, RP; de Almeida, S; Kuhmmer, R; Lazzaretti, RK; Mattevi, VS; Pinheiro, CA; Ribeiro, JP; Silveira, JM; Silveira, MF; Sprinz, E; Turatti, L | 1 |
Carman, T; Hileman, C; Labbato, DE; Longenecker, C; McComsey, G; Milne, G; Storer, Nj; White, C | 1 |
Adorni, F; Bonora, S; Clementi, E; Di Perri, G; Ferraris, L; Galli, M; Gervasoni, C; Milani, G; Peri, A; Riva, A; Tarkowski, M; Viganò, O | 1 |
Bissio, E; Espinola, L; Gadano, A; Gallego, P; Lopardo, G; Stambullian, M | 1 |
Collier, AC; Daar, ES; Fischl, MA; Haas, DW; Mollan, K; Morse, GD; Ribaudo, HJ; Sax, PE; Tierney, C | 1 |
Äbelö, A; Ashton, M; Barrail-Tran, A; Bergstrand, M; Calcagno, A; D'Avolio, A; Gisslén, M; Ormaasen, V; Rekić, D; Röshammar, D; Tarning, J; Vigan, M | 1 |
Abram, M; Cheng, AK; DeJesus, E; Fordyce, MW; Gathe, J; Henry, K; Molina, JM; Plummer, A; Ramanathan, S; Rockstroh, JK; Szwarcberg, J; Wei, X | 1 |
Back, D; Boffito, M; Else, L; Gazzard, B; Jackson, A; Karolia, Z; Moyle, G; Ringner-Nackter, L; Seymour, N; Yapa, MH | 1 |
Chang, JH; Cheong, J; Ho, Q; Lin, M; Plise, E | 1 |
Bertz, R; Botes, M; Conradie, F; Eley, T; Hardy, H; Huang, SP; Josipovic, D; McGrath, D; Osiyemi, O; Zorrilla, CD | 1 |
Bow, DA; Chiou, WJ; de Morais, SM; Kikuchi, R; Li, X; Voorman, RL | 1 |
Apesteguia, AF; Domeque, N; Lozano, R | 1 |
Bernardino, JI; Carton, JA; Curran, A; Domingo, P; Ferrer, E; Gatell, JM; Gonzalez-Cordon, A; Gutierrez, F; Martinez, E; Murillas, J; Negredo, E; Peraire, J; Perez, I; Pich, J; Podzamczer, D; Portilla, J; Santos, I | 1 |
Antoniadou, A; Detsika, M; Hatzakis, A; Katsarolis, I; Panagopoulos, P; Papadopoulos, A; Paraskevis, D; Petrikkos, G; Protopapas, K; Sypsa, V | 1 |
Daar, ES; Haas, DW; Johnson, DH; McLaren, PJ; Morse, GD; Ritchie, MD; Venuto, C | 1 |
Beckman, JA; Goldfine, AB; Milian, J; Parmer, C; Zuflacht, JP | 1 |
Ando, A; Baumer, Y; Byron, MM; Chow, D; Kallianpur, KJ; Keating, S; Kohorn, L; Ndhlovu, L; Shikuma, C; Souza, S | 1 |
Colella, E; Di Cristo, V; Franzetti, M; Galli, M; Giacomelli, A; Oreni, L; Ridolfo, AL; Rusconi, S | 1 |
Berenguer, J; Blanco, JR; Estrada, V; Gómez-Garre, MD; Martínez, E; Masiá, M; Monge, S; Portilla, J; Sobrino, P; Viladés, C | 1 |
Durante, W; Durante, ZE; Liu, XM; Peyton, KJ | 1 |
Listowsky, I; Roy-Chowdhury, J; Roy-Chowdhury, N; Wolkoff, AW | 1 |
Broadhurst, R; Gugsa, S; Heller, T; Hosseinipour, MC; Lim, R; Ngongondo, M; Ongubo, DM; Phiri, S; Speight, C; Stanley, CC; Tembo, P; Tweya, H | 1 |
Ard, KL; Beckman, JA; Milian, J; Prenner, JC; Price, CN; Sax, PE; Solomon, DA; Wood, BR; Zuflacht, JP | 1 |
Baker, P; Chirwa, S; Erdem, H; Haas, DW; Leger, P; Leonard, M; Nwogu, JN; Olson, L; Richardson, DM; Turner, M | 1 |
Cetin, I; Dalzero, S; Degli Antoni, A; Floridia, M; Francisci, D; Frisina, V; Liuzzi, G; Maccabruni, A; Masuelli, G; Ravizza, M; Sansone, M; Simonazzi, G; Tamburrini, E; Tassis, B | 1 |
Becker, KJ; Budoff, M; Burkholder, GA; Chow, FC; Crane, HM; Delaney, JAC; Drozd, DR; Eron, JJ; Geng, E; Heckbert, SR; Ho, EL; Huffer, A; Hunt, PW; Kalani, R; Kim, HN; Kitahata, MM; Mathews, WC; Moore, RD; Nance, RM; Ritchings, C; Rosenblatt, L; Saag, MS; Tirschwell, DL; Whitney, BM; Wood, BR; Zunt, JR | 1 |
Chan, WW; Li, M; Zucker, SD | 1 |
Abdi, A; Bavand, A; Farahani, E; Mazaherpour, H; Mazaherpour, S; Ramezani, A; Sofian, M | 1 |
Chikamoto, J; Hirata, M; Nagahara, M; Omori, H; Otoi, T | 1 |
1 review(s) available for atazanavir sulfate and bilirubin
Article | Year |
---|---|
Family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A): from Gilbert's syndrome to genetic organization and variability.
Topics: Antineoplastic Agents, Phytogenic; Atazanavir Sulfate; Bilirubin; Camptothecin; Genetic Variation; Gilbert Disease; Glucuronosyltransferase; HIV Protease Inhibitors; Humans; Irinotecan; Isoenzymes; Jaundice; Neoplasms; Oligopeptides; Pharmacogenetics; Pyridines; Risk Factors; Terminology as Topic | 2008 |
15 trial(s) available for atazanavir sulfate and bilirubin
Article | Year |
---|---|
Early clinical experience with atazanavir in treatment-experienced patients.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Drug Resistance, Multiple, Viral; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; New South Wales; Oligopeptides; Pyridines; Treatment Outcome; Viral Load | 2006 |
Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy.
Topics: Adult; Atazanavir Sulfate; Bilirubin; CD4 Lymphocyte Count; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pilot Projects; Pyridines; Ritonavir; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2007 |
The bilirubin-increasing drug atazanavir improves endothelial function in patients with type 2 diabetes mellitus.
Topics: Acetylcholine; Aged; Atazanavir Sulfate; Bilirubin; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Humans; Male; Middle Aged; Nitroglycerin; Oligopeptides; Oxidative Stress; Pyridines; Vasodilation; Vasodilator Agents; von Willebrand Factor | 2011 |
Open-label randomized multicenter selection study of once daily antiretroviral treatment regimen comparing ritonavir-boosted atazanavir to efavirenz with fixed-dose abacavir and lamivudine.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alanine Transaminase; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Bilirubin; Cholesterol; Cyclopropanes; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; Humans; Japan; Lamivudine; Oligopeptides; Pyridines; Ritonavir; Treatment Outcome | 2011 |
Bilirubin-a potential marker of drug exposure in atazanavir-based antiretroviral therapy.
Topics: Atazanavir Sulfate; Bilirubin; Biomarkers; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pyridines | 2011 |
Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Female; Glucuronosyltransferase; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Polymorphism, Genetic; Prospective Studies; Pyridines; Treatment Outcome; Triglycerides | 2012 |
Short communication: fasting increases serum concentrations of bilirubin in patients receiving atazanavir: results from a pilot study.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Fasting; Female; HIV Infections; Humans; Hyperbilirubinemia; Male; Middle Aged; Oligopeptides; Pyridines; Serum | 2013 |
Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Bilirubin; Genetic Variation; Genotype; Glucuronosyltransferase; HIV Infections; HIV-1; Humans; Jaundice; Oligopeptides; Pyridines; Ritonavir | 2013 |
A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Aspartate Aminotransferases; Atazanavir Sulfate; Bilirubin; Bone Density; Carbamates; Cobicistat; Confidence Intervals; Creatinine; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Quinolones; Ritonavir; RNA, Viral; Tenofovir; Thiazoles; Triglycerides | 2013 |
Coadministration of atazanavir-ritonavir and zinc sulfate: impact on hyperbilirubinemia and pharmacokinetics.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Bilirubin; Confidence Intervals; Cross-Over Studies; Drug Administration Schedule; Drug Therapy, Combination; Drug Tolerance; Female; HIV Infections; HIV-1; Humans; Hyperbilirubinemia; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Young Adult; Zinc Sulfate | 2013 |
Clinical and pharmacogenetic factors affecting neonatal bilirubinemia following atazanavir treatment of mothers during pregnancy.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Female; Glucuronosyltransferase; HIV Infections; Humans; Hyperbilirubinemia; Infant, Newborn; Oligopeptides; Plasma; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Pyridines; Ritonavir | 2013 |
Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir.
Topics: Adult; Atazanavir Sulfate; Bilirubin; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Darunavir; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Lipids; Male; Middle Aged; Oligopeptides; Prospective Studies; Pyridines; Ritonavir; RNA, Viral; Spain; Sulfonamides | 2014 |
Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Bilirubin; Female; Genome-Wide Association Study; Glucuronosyltransferase; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polymorphism, Single Nucleotide; Prospective Studies; Pyridines; Ritonavir | 2014 |
Atazanavir improves cardiometabolic measures but not vascular function in patients with long-standing type 1 diabetes mellitus.
Topics: Adult; Antioxidants; Atazanavir Sulfate; Atherosclerosis; Bilirubin; Blood Pressure; Cardiovascular System; Cholesterol, LDL; Diabetes Mellitus, Type 1; Endothelium, Vascular; Female; Humans; Male; Middle Aged; Oxidative Stress; Risk Factors; Vasodilation | 2015 |
Conflicting effects of atazanavir therapy on atherosclerotic risk factors in stable HIV patients: A randomized trial of regimen switch to atazanavir.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Atherosclerosis; Bilirubin; Biomarkers; Cross-Sectional Studies; Endothelium, Vascular; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oxidative Stress; Risk Factors; Viral Load | 2017 |
37 other study(ies) available for atazanavir sulfate and bilirubin
Article | Year |
---|---|
In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation.
Topics: Atazanavir Sulfate; Bilirubin; Dose-Response Relationship, Drug; Drug Interactions; Glucuronosyltransferase; HIV Protease Inhibitors; Humans; In Vitro Techniques; Indinavir; Kinetics; Microsomes, Liver; Oligopeptides; Pyridines; Recombinant Proteins | 2005 |
Use of bilirubin as a marker of adherence to atazanavir-based antiretroviral therapy.
Topics: Adult; Atazanavir Sulfate; Bilirubin; Biomarkers; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Patient Compliance; Pyridines; Retrospective Studies; Treatment Outcome; Viral Load | 2005 |
Can boosted atazanavir induce hyperlipotrophy?
Topics: Aged; Atazanavir Sulfate; Bilirubin; Female; Hepatitis C; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Oligopeptides; Protease Inhibitors; Pyridines | 2006 |
Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.
Topics: Adult; Atazanavir Sulfate; Bilirubin; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Saquinavir; Statistics, Nonparametric | 2006 |
Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.
Topics: Adult; Atazanavir Sulfate; Bilirubin; Cohort Studies; Drug Monitoring; Drug Resistance, Viral; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Mutation; Netherlands; Oligopeptides; Plasma; Pyridines; Retrospective Studies; Treatment Outcome | 2007 |
Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Chromatography, High Pressure Liquid; Cross-Sectional Studies; Drug Administration Schedule; Drug Monitoring; Female; HIV Infections; Humans; Male; Oligopeptides; Pyridines; Ritonavir | 2007 |
Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis.
Topics: Adult; Age Factors; Atazanavir Sulfate; Bilirubin; CD4 Lymphocyte Count; Female; Hepatitis B; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Liver Cirrhosis; Male; Oligopeptides; Pyridines; Ritonavir; Transaminases | 2008 |
Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Chromatography, High Pressure Liquid; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Retrospective Studies; Ritonavir; Tenofovir | 2008 |
Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin.
Topics: Adult; Antiviral Agents; Atazanavir Sulfate; Bilirubin; Drug Interactions; Female; Glucuronosyltransferase; Hepacivirus; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Male; Middle Aged; Oligopeptides; Pyridines; Ribavirin | 2008 |
The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients.
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Bilirubin; Chromatography, High Pressure Liquid; Clinical Trials as Topic; Cyclopropanes; Drug Interactions; HIV-1; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Failure; Treatment Outcome; Viral Load | 2010 |
Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection.
Topics: Adult; Atazanavir Sulfate; Bilirubin; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Pyridines; Retrospective Studies; Ritonavir; Treatment Outcome; Viral Load | 2010 |
Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bilirubin; Female; Gene Frequency; Genes, MDR; Glucuronosyltransferase; HIV Infections; Humans; Hyperbilirubinemia; Korea; Logistic Models; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polymorphism, Genetic; Pyridines; Risk Factors; Sequence Analysis, DNA; Severity of Illness Index | 2010 |
HIV-infected adolescents: relationship between atazanavir plasma levels and bilirubin concentrations.
Topics: Adolescent; Adolescent Health Services; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Child; Drug Administration Schedule; Drug Monitoring; Female; HIV Infections; Humans; Hyperbilirubinemia; Male; Oligopeptides; Pyridines; Spain | 2011 |
Detrimental effect of atazanavir plasma concentrations on total serum bilirubin levels in the presence of UGT1A1 polymorphisms.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Female; Glucuronosyltransferase; Humans; Male; Middle Aged; Oligopeptides; Plasma; Polymorphism, Genetic; Pyridines | 2011 |
Short communication: use of serum bilirubin levels as surrogate marker of early virological response to atazanavir-based antiretroviral therapy.
Topics: Adult; Alleles; Atazanavir Sulfate; Bilirubin; Biomarkers; CD4 Lymphocyte Count; Coinfection; Female; Follow-Up Studies; Glucuronosyltransferase; Hepatitis C; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Odds Ratio; Oligopeptides; Pyridines; Regression Analysis; Retrospective Studies; RNA, Viral; ROC Curve; Viral Load | 2011 |
The use of atazanavir in HIV-infected patients with liver cirrhosis: lack of hepatotoxicity and no significant changes in bilirubin values or model for end-stage liver disease score.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; End Stage Liver Disease; Female; HIV Infections; HIV-1; Humans; Liver Cirrhosis; Male; Oligopeptides; Pyridines | 2011 |
Atazanavir in pregnancy: impact on neonatal hyperbilirubinemia.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Bilirubin; Cohort Studies; Female; Fetal Blood; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia, Neonatal; Infant, Newborn; Jaundice, Neonatal; Male; Maternal-Fetal Exchange; Medical Records; Oligopeptides; Phototherapy; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Pyridines; Retrospective Studies; Ritonavir | 2011 |
Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Bilirubin; Cohort Studies; Cyclopropanes; Darunavir; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Nephrolithiasis; Oligopeptides; Pyridines; Pyrimidinones; Retrospective Studies; Ritonavir; Sulfonamides | 2011 |
Short communication: UGT1A1*28 variant allele is a predictor of severe hyperbilirubinemia in HIV-infected patients on HAART in southern Brazil.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alleles; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Bilirubin; Brazil; Cross-Sectional Studies; Female; Genotype; Glucuronosyltransferase; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Indinavir; Male; Oligopeptides; Predictive Value of Tests; Pyridines; Risk Factors; Severity of Illness Index | 2012 |
Relationship between total bilirubin and endothelial function, inflammation and oxidative stress in HIV-infected adults on stable antiretroviral therapy.
Topics: Adult; Atazanavir Sulfate; Bilirubin; Blood Flow Velocity; Brachial Artery; C-Reactive Protein; Cell Adhesion Molecules; Cross-Sectional Studies; Endothelium, Vascular; F2-Isoprostanes; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; HIV Protease Inhibitors; HIV Seropositivity; Humans; Inflammation; Interleukin-6; Male; Middle Aged; Oligopeptides; Oxidative Stress; Pyridines; Retrospective Studies; Tumor Necrosis Factor-alpha; Vasodilation | 2012 |
External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1-infected patients.
Topics: Adult; Atazanavir Sulfate; Bilirubin; Biomarkers; Computer Simulation; Drug Monitoring; Drug Therapy, Combination; Europe; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Medication Adherence; Middle Aged; Nomograms; Oligopeptides; Pyridines; Reproducibility of Results; Ritonavir | 2013 |
Evaluating the in vitro inhibition of UGT1A1, OATP1B1, OATP1B3, MRP2, and BSEP in predicting drug-induced hyperbilirubinemia.
Topics: Atazanavir Sulfate; Bilirubin; Cell Line; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Indinavir; Liver-Specific Organic Anion Transporter 1; Models, Biological; Oligopeptides; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Pyridines; Solute Carrier Organic Anion Transporter Family Member 1B3 | 2013 |
In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia.
Topics: Antirheumatic Agents; Atazanavir Sulfate; Bilirubin; Carbamates; Cyclosporine; Furans; Glucuronosyltransferase; HIV Protease Inhibitors; Hyperbilirubinemia; In Vitro Techniques; Indinavir; Liver-Specific Organic Anion Transporter 1; Oligopeptides; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Pyridines; Rifampin; Rifamycins; Saquinavir; Solute Carrier Organic Anion Transporter Family Member 1B3; Sulfonamides | 2014 |
Extended mathematical model for "in vivo" quantification of the interaction betweeen atazanavir and bilirubin.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Biomarkers, Pharmacological; Drug Therapy, Combination; Female; Glucuronosyltransferase; HIV Infections; HIV Protease Inhibitors; Humans; Male; Models, Theoretical; Oligopeptides; Polymorphism, Genetic; Pyridines; Young Adult | 2014 |
High prevalence of the UGT1A1*28 variant in HIV-infected individuals in Greece.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Bilirubin; Cross-Sectional Studies; Glucuronosyltransferase; Greece; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Middle Aged; Oligopeptides; Pharmacogenetics; Polymorphism, Genetic; Prevalence; Pyridines; Ritonavir | 2014 |
Atazanavir use and carotid intima media thickness progression in HIV: potential influence of bilirubin.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Atherosclerosis; Bilirubin; Carotid Intima-Media Thickness; Female; HIV Infections; Humans; Male; Retrospective Studies | 2016 |
Factors involved in continuance of atazanavir-based regimens: Results from a cohort of HIV1-positive patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Bilirubin; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Retrospective Studies; Ritonavir; RNA, Viral; Treatment Failure; Viral Load | 2016 |
Relationship between plasma bilirubin level and oxidative stress markers in HIV-infected patients on atazanavir- vs. efavirenz-based antiretroviral therapy.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Bilirubin; Biomarkers; Cyclopropanes; Female; HIV Infections; Humans; Lipoproteins, LDL; Male; Oxidative Stress; Peroxidase; Phospholipases A2; Plasma; Prospective Studies | 2016 |
Heme oxygenase-1-derived bilirubin counteracts HIV protease inhibitor-mediated endothelial cell dysfunction.
Topics: Acetylcysteine; Atazanavir Sulfate; Bilirubin; Cardiovascular Diseases; Cell Proliferation; Endothelial Cells; Gene Expression Regulation; Heme Oxygenase-1; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; NF-E2-Related Factor 2; Promoter Regions, Genetic; Reactive Oxygen Species; Ritonavir; Rotenone | 2016 |
Drug- and Drug Abuse-Associated Hyperbilirubinemia: Experience With Atazanavir.
Topics: Animals; Atazanavir Sulfate; Bilirubin; Cells, Cultured; Female; Glucuronosyltransferase; Glutathione Transferase; Hepatocytes; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Male; Rats, Wistar; Ritonavir; Substance-Related Disorders | 2017 |
A cross-sectional study to evaluate second line virological failure and elevated bilirubin as a surrogate for adherence to atazanavir/ritonavir in two urban HIV clinics in Lilongwe, Malawi.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Biomarkers, Pharmacological; CD4 Lymphocyte Count; Cross-Sectional Studies; Female; HIV Infections; Humans; Malawi; Male; Medication Adherence; Middle Aged; Ritonavir; Treatment Failure; Urban Health; Viral Load | 2017 |
Race/ethnicity difference in the pharmacogenetics of bilirubin-related atazanavir discontinuation.
Topics: Adult; Atazanavir Sulfate; Bilirubin; Black or African American; Female; Genetic Association Studies; Genotype; Glucuronosyltransferase; Hispanic or Latino; HIV Infections; HIV Protease Inhibitors; Humans; Jaundice; Male; Middle Aged; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; White People | 2018 |
Atazanavir and darunavir in pregnant women with HIV: evaluation of laboratory and clinical outcomes from an observational national study.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Cholesterol; Darunavir; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Infant; Infant, Newborn; Male; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Treatment Outcome; Triglycerides; Viral Load | 2018 |
Association Between Bilirubin, Atazanavir, and Cardiovascular Disease Events Among People Living With HIV Across the United States.
Topics: Adult; Atazanavir Sulfate; Bilirubin; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Myocardial Infarction; United States | 2019 |
Association Between Atazanavir-Induced Hyperbilirubinemia and Cardiovascular Disease in Patients Infected with HIV.
Topics: Atazanavir Sulfate; Bilirubin; Cardiovascular Diseases; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Ischemic Stroke; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Retrospective Studies; Time Factors | 2020 |
Comparing Outcomes of Two Antiviral Therapy Combinations among COVID-19 Patients.
Topics: Aged; Antiviral Agents; Arrhythmias, Cardiac; Atazanavir Sulfate; Bilirubin; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Therapy, Combination; Female; Hospitalization; Humans; Hydroxychloroquine; Length of Stay; Lopinavir; Male; Middle Aged; Ritonavir; SARS-CoV-2; Treatment Outcome | 2022 |
Evaluating variations in bilirubin glucuronidation activity by protease inhibitors in canine and human primary hepatocytes cultured in a 3D culture system.
Topics: Animals; Atazanavir Sulfate; Bilirubin; Dogs; Hepatocytes; Humans; Liver; Protease Inhibitors; Ritonavir; Spheroids, Cellular | 2023 |